RepliCel Life Sciences P/E
Quel est le P/E de RepliCel Life Sciences?
Le P/E de RepliCel Life Sciences, Inc. est N/A
Quelle est la définition de P/E?
Le ratio cours / bénéfice est le rapport entre le prix des actions d'une entreprise et le bénéfice par action de l'entreprise calculé sur les douze derniers mois.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E des entreprises dans Health Care secteur sur TSXV par rapport à RepliCel Life Sciences
Que fait RepliCel Life Sciences?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Entreprises avec p/e similaire à RepliCel Life Sciences
- Catalent a P/E de N/A
- BP Plc a P/E de N/A
- GrowGeneration a P/E de N/A
- PetroFrontier a P/E de N/A
- StoneMor Inc a P/E de N/A
- Truecar Inc a P/E de N/A
- RepliCel Life Sciences a P/E de N/A
- SPDR MSCI Europe UCITS ETF a P/E de N/A
- Reaves Utility Income Fund a P/E de N/A
- AgJunction a P/E de N/A
- ABIONYX Pharma SA a P/E de N/A
- Pacific Horizon Investment Trust Plc a P/E de N/A
- EJF Investments a P/E de N/A